Remnant Ablation, Adjuvant Treatment and Treatment of Locoregional Metastases with 131I-Reference-Cited by-同舟云学术

Remnant Ablation, Adjuvant Treatment and Treatment of Locoregional Metastases with 131I

Published:2016 Issue: Volume: Page:395-409
ISSN:
Container-title:Thyroid Cancer
language:
Short-container-title:

Author:

Van Nostrand Douglas

Publisher

Springer New York

Link

http://link.springer.com/content/pdf/10.1007/978-1-4939-3314-3_33

Reference75 articles.

1. Khorjekar G, Van Nostrand D, Kharazi P, Kulkarni K, Garcia C, Acio E, Atkins F. Division of Nuclear Medicine, Washington Hospital Center. Washington, D.C. Can the controversy regarding selecting the prescribed activity of 131I for first-time therapies in patient with differentiation thyroid cancer be reduced by defining the terms? An educational exhibit. J Nucl Med. 2011;52S(abstract).

2. Haugen BR, Alexander EA, Bible KC, Doherty G, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, Schuff K, Sherman SI, Sosa JA, Steward DL, Tuttle RM, Wartofsky L. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26:1–133.

3. Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JWA, Wiersinga W, The European Thyroid Cancer Taskforce. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol. 2006;154:787–803.

4. Perros P, Colley S, Boelaert K, Evans C, Evans RM, Gerrard GE, Gilbert JA, Harrison B, Johnson SJ, Giles TE, Moss L, Lewington V, Newbold KL, Taylor J, Thakker RV, Watkinson J, Williams GR. British Thyroid Association guidelines for the management of thyroid cancer. Clin Endocrinol. 2014;81 Suppl 1:1–122.

5. National Comprehensive Cancer Network (NCCN). Clinical practice guidelines in oncology. Thyroid carcinoma. Follicular thyroid carcinoma. V.2.2015. www.nccn.org .